

Remarks

Claims 141-144, 146-150, and 152 are withdrawn from consideration in response to the Examiner's restriction requirement as part of a non-elected Group. Applicants reserve the right to prosecute such claims in a divisional application. Applicants have amended Claims 138-140 and assert that that no new matter has been added and that basis for the amendments can be found on pages 11-14 and throughout the specification as filed.

Thus, Claims 138-140, 145 and 150 are currently pending. Once the currently pending claims are allowed, Applicants respectfully request that the Examiner consider rejoinder of Claims 146 and 152 since these claims depend from or otherwise require all the limitations of the allowable claims and meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112.

Respectfully submitted,

/Lynn D. Apelgren/
Lynn D. Apelgren
Attorney for Applicants
Registration No. 45,341
Phone: 317-276-6501

Eli Lilly and Company
Patent Division/LDA
P.O. Box 6288
Indianapolis, Indiana 46206-6288

October 29, 2008